We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

6 hedge funds and large institutions have $10.4K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding

Funds holding: 5 → 6 (+1)

1% more capital invested

Capital invested by funds: $10.2K → $10.4K (+$147)

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AW
Atlas Wealth
Ohio
+$999

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$5.1K – – –
WPA
2
Wealth Preservation Advisors
Tennessee
$2.68K – – –
ACM
3
Academy Capital Management
Texas
$1.02K – – –
AW
4
Atlas Wealth
Ohio
$999 +$999 +19,620 New
FS
5
Financial Symmetry
North Carolina
$581 – – –

PVCT Hedge Fund Activity: Q1 2026 in Review

6 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q1 2026, worth a combined $10.4K — up 1.4% from $10.2K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PVCT positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Atlas Wealth, opening a new position worth an estimated $999.

  • 6 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q1 2026, up from 5 in Q4 2025.
  • Funds reported $10.4K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q1 2026, up 1.4% quarter-over-quarter.
  • 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q1 2026 and 0 closed out, a net change of +1 holder.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q1 2026 was Atlas Wealth, an estimated $999 added.

Based on aggregated 13F filings for Q1 2026.